FSH (follicle stimulating hormone) — the perimenopause signal

Paired condition: Perimenopause lab panel

Quick answer

FSH is a pituitary hormone that signals the ovaries (in women) or testes (in men) to mature follicles or produce sperm. In women, FSH rises as ovarian function declines — making it the most-recognized lab signal of perimenopause and menopause. But in perimenopause especially, FSH *fluctuates* dramatically week to week, and a single FSH value is often misleading. AMH (anti-Müllerian hormone) is a more stable companion marker for ovarian reserve assessment.

Reference ranges and interpretation

Value / population	Classification	What it means
Reproductive-age female, early follicular (day 2–5)	3 – 10 mIU/mL	Adequate ovarian reserve in most cases.
Reproductive-age female, ovulation	5 – 20 mIU/mL	Mid-cycle surge.
Reproductive-age female, luteal	1 – 9 mIU/mL	Post-ovulation suppression.
Postmenopausal female	> 25 (often 50 – 130) mIU/mL	Sustained elevation; brain shouting at non-responsive ovaries.
Adult male	1.4 – 18.1 mIU/mL	Standard range. Elevation suggests primary testicular failure.
Prepubertal	< 5 mIU/mL	Pre-puberty baseline.

In cycling women, FSH must be interpreted relative to cycle day. A day 3 FSH of 12 has different meaning than a mid-luteal FSH of 12.

What different values typically indicate (women)

Day 3 FSH < 10: generally consistent with adequate ovarian reserve. Normal reproductive function. Doesn't rule out impending perimenopause if pattern across multiple panels is trending upward.

Day 3 FSH 10 – 15: "diminished ovarian reserve" territory. Often paired with AMH < 1.0 and reduced antral follicle count. Fertility implications are real but variable. Many women in this range still conceive naturally.

Day 3 FSH 15 – 25: advanced perimenopause. AMH typically very low. Cycles often becoming irregular. Hormonal fluctuation can be substantial.

FSH > 25 (sustained, particularly with low estradiol): consistent with menopause. Definitive diagnosis still requires 12 consecutive months without menstruation, but the lab pattern supports the clinical picture.

Highly variable FSH (e.g., 28 → 9 → 22 across recent panels): the classic perimenopause signature. The variability itself is diagnostic of late perimenopause more than any single value.

What different values typically indicate (men)

FSH < 1.4 (low): secondary hypogonadism (pituitary or hypothalamic). The brain isn't signaling. Common in metabolic dysfunction, exogenous T use, opioid use, pituitary issues.

FSH 1.4 – 18.1: standard range. Specific position within this range tells you about spermatogenesis activity in the context of fertility evaluation.

FSH > 18 (high): primary testicular failure. The brain is shouting (high FSH and usually high LH) because the testes aren't responding. Causes include prior chemotherapy, undescended testicles, infections, autoimmune, or aging.

What to look at alongside FSH

For women, the perimenopause / fertility / menopause picture lives in:

- LH — companion gonadotropin; ratio shifts in late perimenopause
- Estradiol — fluctuates dramatically in perimenopause; high or low values both occur
- Progesterone (luteal phase) — drops earlier than estradiol in perimenopause
- AMH — far more stable than FSH; reflects ovarian reserve directly
- Antral follicle count (ultrasound) — companion ovarian reserve measure
- TSH + free T4 — thyroid dysfunction overlaps and confuses interpretation
- Prolactin — high prolactin can suppress FSH; check before drawing conclusions

For men, the panel includes total + free testosterone, SHBG, LH, FSH, estradiol, prolactin — see the [low testosterone condition page](/lab-results/low-testosterone-men).

Why a single FSH is often misleading in perimenopause

In a 45-year-old woman entering perimenopause, FSH can be 9 in one cycle and 28 in the next. The same patient with cycle-by-cycle FSH variation can have:

- Highly fluctuating estradiol (often higher than reproductive norms before dropping)
- Progesterone deficit (anovulatory cycles)
- Symptoms (hot flashes, mood lability, sleep changes) that come and go

The point isn't to dismiss FSH — it's to interpret it across multiple draws and against the rest of the picture. AMH is more stable; symptom pattern is often more informative than any single hormone draw.

Phi Longevity reads every marker on every lab you upload — together, against your history, against optimal ranges, and across time. The integrated picture tells you what a single number can't.

Start with my labs →

Frequently asked questions

My FSH is 14 — am I in menopause?

Probably not yet, especially if you're still cycling. FSH 14 is consistent with diminished ovarian reserve and early-to-mid perimenopause. Sustained FSH > 25 across multiple draws over 12+ months with absent menstruation is closer to the menopause diagnosis.

Should I test FSH or AMH for ovarian reserve?

Ideally both. AMH is more stable (doesn't fluctuate with cycle day) and better reflects ovarian follicle reserve. FSH is more widely available and gives a complementary read. For fertility planning, both plus an antral follicle count on ultrasound is the gold standard.

When in my cycle should FSH be drawn?

Cycle day 2–5 (early follicular phase). FSH varies substantially across the cycle; the early follicular window is the standard for fertility / reserve evaluation.

My FSH is high but I still get periods. Am I infertile?

Not necessarily. Elevated FSH suggests diminished ovarian reserve but doesn't preclude pregnancy. Many women conceive with FSH > 15 — though success rates decline. A fertility specialist evaluation is appropriate if pregnancy is a goal.

Why does my doctor say "FSH alone isn't enough" for diagnosing menopause?

Because of cycle-to-cycle variability. A single FSH value in perimenopause can be quite normal; the trajectory and pattern matter more. The clinical menopause diagnosis (12 consecutive months without menstruation) is more reliable than any single lab value.

Can hormone therapy affect FSH?

Yes. Estrogen replacement suppresses FSH (the brain stops shouting once estradiol is adequate). On HT, FSH and estradiol are sometimes monitored to titrate dose, though many providers manage HT by symptoms rather than labs.

References

All citations verified against PubMed / publisher of record 2026-05-26.

1.Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ; STRAW 10 Collaborative Group. (2012). Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 19(4):387-395. — STRAW+10: current standard staging system for reproductive aging. Defines the menstrual + FSH + AMH + antral-follicle-count criteria across reproductive, perimenopausal, and postmenopausal stages.PubMed →DOI →
2."The 2022 Hormone Therapy Position Statement of The North American Menopause Society" Advisory Panel. (2022). Menopause. 29(7):767-794. — Standard for HT decision-making framework in late perimenopause / menopause referenced in this page's FAQ.PubMed →DOI →
3.Bhasin S, Brito JP, Cunningham GR, et al. (2018). Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 103(5):1715-1744. — Reference for the men's-section FSH framing (primary testicular failure produces elevated FSH; secondary hypogonadism produces low FSH).PubMed →DOI →
4.Iliodromiti S, Kelsey TW, Anderson RA, Nelson SM. (2013). Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. Journal of Clinical Endocrinology & Metabolism. 98(8):3332-3340. — Systematic review of AMH as a diagnostic biomarker for PCOS; supports the "AMH is more stable than FSH and better reflects ovarian reserve" framing in this page. Optimal AMH threshold for PCOS diagnosis: 4.7 ng/mL.PubMed →DOI →

FSH reference ranges quoted are typical US clinical laboratory ranges; specific cutoffs vary by assay and lab. The "cycle day 2–5" timing recommendation for FSH and the "FSH variability in perimenopause" framing are well-established in STRAW+10. Every link above opens the PubMed abstract or publisher's DOI landing page in a new tab. All citations verified vs PubMed / publisher of record 2026-05-26.

By Steve Pinedo

Co-founder, Phi Longevity

Last updated: 2026-05-26

Steve Pinedo is the Co-founder of Phi Longevity, the AI application that turns a confusing stack of lab reports, wearable data, and clinical notes into a single, integrated picture of your health. He started Phi Longevity to make proactive health and wellness far easier to achieve. He realized how difficult it was for clients to manage their own care, records and coordination so he assembled a comprehensive M.D. led clinical team behind the platform, packaging the proactive-care experience that delivered measurable outcomes (lower triglycerides, reduced body fat, improved LDL, balanced hormones, relief from long-running autoimmune conditions) for any patient with a complicated lab to use now with an application. More about Phi Longevity →

Perimenopause lab panel

The full multi-hormone pattern this signal lives in.

PCOS lab work

Where the LH/FSH ratio and AMH context matter.

TSH biomarker

Thyroid dysfunction that confuses interpretation.